{"id":6895,"date":"2024-12-06T13:56:05","date_gmt":"2024-12-06T12:56:05","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=clinical-trial&p=6895"},"modified":"2025-08-08T11:23:17","modified_gmt":"2025-08-08T09:23:17","slug":"sequoia-trial","status":"publish","type":"clinical-trial","link":"https:\/\/beonemedaffairs.com\/us\/clinical-trial\/6895\/sequoia-trial\/","title":{"rendered":"SEQUOIA Trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6895","clinical-trial","type-clinical-trial","status-publish","hentry","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-zanubrutinib"],"acf":{"summary":"SEQUOIA (NCT03336333) is a global Phase 3, open-label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in patients with previously untreated chronic lymphocytic leukemia (CLL).","study_status":"ongoing","cancer_type":false,"authors":"","related_posts":[{"id":7296,"title":"SEQUOIA Trial","title_guest":"","summary":"SEQUOIA (NCT03336333) is a global Phase 3, open-label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in patients with previously untreated chronic lymphocytic leukemia (CLL).","summary_guest":"","content-type":4,"post_image":7437,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7296\/sequoia-trial\/","date":"2025-05-28T16:13:34","date_gmt":"2025-05-28T14:13:34"}],"content-type":246,"download_file_reading":null,"display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","videolange":null,"fliphtml_link":""},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/clinical-trial\/6895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/clinical-trial"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/clinical-trial"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7296"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6895"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}